Translations:SGLT2 inhibitor/27/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
14,847 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 19:46, 12 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (SGLT2 inhibitor)
Dapagliflozin disposition is not evidently affected by BMI or [[body weight]], therefore the pharmacokinetic findings are expected to be applicable to patients with a higher [[Body mass index|BMI]]. Dapagliflozin resulted in [[dose-dependent]] increases excretions in urinary glucose, up to 47g/d following single-dose administration, which can be expected from its [[mechanism of action]], dapagliflozin.

Dapagliflozin disposition is not evidently affected by BMI or body weight, therefore the pharmacokinetic findings are expected to be applicable to patients with a higher BMI. Dapagliflozin resulted in dose-dependent increases excretions in urinary glucose, up to 47g/d following single-dose administration, which can be expected from its mechanism of action, dapagliflozin.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:SGLT2_inhibitor/27/en&oldid=113856"